ClinicalTrials.gg

Program

PfSPZ Challenge

Also written as “PfSPZ Challenge (7G8)”, “PfSPZ Challenge (for CHMI)” and “PfSPZ Challenge (NF54)”.

Its studies are mostly in Malaria · Malaria, Falciparum, led by Sanaria.

Furthest: phase 1, since Oct 22, 200914 company-led studies, 1 open or runningNext primary completion: Aug 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanaria141 open or runningphase 1since Oct 22, 2009Oct 22, 2009Aug 30, 2027phase 1 · NCT06862453

Also a collaborator on its studies: marathon-oil-corporation and noble-oil-services.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 22, 2009First study: phase 1 study in Malaria, FalciparumFirst studyNCT01001650 · 80 enrolled · United States
  2. Mar 11, 2010Phase 1 study in MalariaNCT01086917 · 18 enrolled · Netherlands
  3. Feb 23, 2012Phase 1 study in MalariaNCT01540903 · 30 enrolled · Tanzania
  4. Jun 19, 2012Phase 1 study in MalariaNCT01624961 · 30 enrolled · Germany
  5. Nov 6, 2012Phase 1 study in MalariaNCT01728701 · 30 enrolled · Netherlands
  6. Jan 8, 2013Phase 1 study in MalariaNCT01771848 · 36 enrolled · Spain
  7. Apr 11, 20142 phase 1 studies in MalariaNCT02115516, NCT02132299
  8. Aug 27, 2014Phase 1 study in Malaria, FalciparumNCT02237586 · 25 enrolled · Gabon
  9. Nov 17, 2015Phase 1 study in MalariaNCT02613520 · 105 enrolled · Tanzania
  10. Mar 1, 2016Phase 1 study in MalariaNCT02704533 · 45 enrolled · Germany
  11. Jul 27, 2016Phase 1 study in MalariaNCT02859350 · 135 enrolled · Equatorial Guinea
  12. Dec 13, 2017Phase 1 study in MalariaNCT03420053 · 21 enrolled · Tanzania
  13. Mar 2, 2025Phase 1 study in Malaria, FalciparumNCT06862453 · 42 planned · Germany

Ahead

  1. Aug 30, 2027Primary completion: phase 1 study in Malaria, FalciparumNCT06862453

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06862453Malaria, Falciparum · Germany1RecruitingAug 30, 202742
NCT03420053Malaria · Tanzania1CompletedAug 25, 201821
NCT02859350Malaria · Equatorial Guinea1CompletedDec 2017135
NCT02704533Malaria · Germany1CompletedOct 19, 201845
NCT02613520Malaria · Tanzania1CompletedFeb 2017105
NCT02237586Malaria, Falciparum · Gabon1CompletedSep 201425
NCT02132299Malaria · Tanzania1CompletedJul 201567
NCT02115516Malaria · Germany1CompletedDec 201567
NCT01771848Malaria · Spain1CompletedMay 201336
NCT01728701Malaria · Netherlands1CompletedDec 201330
NCT01624961Malaria · Germany1CompletedOct 201230
NCT01540903Malaria · Tanzania1CompletedSep 201230
NCT01086917Malaria · Netherlands1CompletedFeb 201118
NCT01001650Malaria, Falciparum · United States1CompletedJul 201080

How it is read

Names in the registry

  • “PfSPZ Challenge”, 9 entries
  • “PfSPZ Challenge (7G8)”, 2 entries
  • “PfSPZ Challenge (for CHMI)”, 2 entries
  • “PfSPZ Challenge (NF54)”, 1 entry
  • “PfSPZ Challenge (for PfSPZ-CVac)”, 1 entry

Codes read as this program: NF54.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.